346 results about "Phagocytosis" patented technology

The present invention relates to transmissible elements (e.g. conjugative plasmids, phage and phagemid) which are engineered to express molecules of interest (MOIs) and a pathway modification system (PMS) which is able to introduce mutations in target endogenous genes in a recipient bacterium, or is able to produce nucleic acids which inhibit or increase expression of target endogenous genes in a recipient bacterium, or is able to express peptide inhibitor molecules which inhibit a target endogenous protein in a recipient bacterium. The invention relates to host cells containing the transmissible elements, to pharmaceutical compositions containing such transmissible elements or host cells, and their use in the treatment of various diseases.

The invention relates to a water-soluble carbon chain substance for adjusting transmembrane transport and fluidity of a cell membrane, and preparation and application thereof. The water-soluble carbon chain substance comprises a carbon chain originally having certain water solubility, and the structure of the water-soluble carbon chain substance comprises at least one or more hydrophobic carbon chain parts and one or more hydrophilic groups or residues; the hydrophobic carbon chain part is coupled with water-soluble molecules to form a high-hydrophilicity compound; the water-soluble carbon chain can be used for preventing and treating infections including viruses, bacteria and fungi; anti-aging; the occurrence of neurodegenerative diseases such as Alzheimer's disease is prevented and reduced; by reducing the non-specific phagocytosis of the nano-drug by cells, the effect of the nano-drug on a target focus is enhanced.

The invention relates to a soft electronic device based on a particle phagocytosis effect and a preparation method thereof, and the preparation method comprises the following steps: S1, attaching a hollow mask plate to a polymer substrate, and controlling the position where the polymer substrate can be printed; s2, uniformly dispersing micro-nano particles on the mask plate, wherein the micro-nano particles are in contact with the polymer substrate at the hollowed-out part of the hollowed-out mask plate; s3, after the micro-nano particles make contact with the polymer substrate, the micro-nano particles gradually enter the polymer substrate through the particle phagocytosis effect, and a functional composite material is formed; and S4, removing the hollow mask plate to form the soft electronic device. According to the method, the micro / nano material is directly printed in the soft polymer matrix without introducing a solvent, so that chemical incompatibility and complex fluid dynamic behaviors are avoided. The surface energy-driven particle phagocytosis phenomenon is utilized to realize deep embedding of the material, spontaneous generation is realized, and additional introduction of energy is not needed. Different materials can be seamlessly integrated into the high-performance elastic electronic equipment. Multi-material wireless electronic equipment is created through a multi-layer phagocytic printing technology, and layered printing can be achieved.

The invention discloses an application of a polysaccharide monomer separated from schisandra chinensis in preparation of a PD-L1 + TAMs activator. A large number of experiments show that the polysaccharide monomer schisanan B separated from schisandra chinensis can effectively activate PD-L1 + TAMs cell subsets, so that the phagocytosis of TAMs is enhanced, and the proliferation of tumor cells is inhibited; therefore, it is determined that the polysaccharide monomer schisanan B separated from schisandra chinensis can serve as a natural PD-L1 + TAMs cell subset activator to be used for treating cancers such as non-small cell lung cancer, intestinal cancer, melanoma, urothelial carcinoma or liver cancer, and the polysaccharide monomer schisanan B has the advantages of being free of toxic and side effects, low in price, wide in adaptive patient population and the like.

The invention belongs to the technical field of biological medicines, and particularly relates to a method for promoting polarization and phagocytosis of macrophages by using nicotine and application. It is found that 10 [mu] M nicotine promotes polarization of macrophages to M1 type macrophages and M2 type macrophages, the macrophages are induced to generate proinflammatory factors to regulate the functions of the macrophages, and phagocytosis of the macrophages is enhanced. The invention provides a new method for inducing polarization of macrophages, promoting the macrophages to generate pro-inflammatory cytokines and promoting phagocytosis of the macrophages, and provides a new idea for the new function and application of nicotine which is a tobacco active ingredient.

Provided is a bispecific antibody against EGFR and c-MET. By means of engineering the amino acid sequences of the Fc segments of binding arms, a KIH structure is formed between the EGFR binding arm and C-Met binding arm of the bispecific antibody, thereby assembling a heterodimer. The bispecific antibody is capable of inhibiting the growth and proliferation of EGFR and / or c-Met positive human tumor cells, mediating antibody-dependent cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), and mediating the internalization and degradation of dual target proteins of EGFR and c-MET, and also has a synergistic effect. The bispecific antibody is simple to prepare and stable in structure, and is expected to better meet clinical treatment requirements on the basis of a better tumor cell selectivity.

A fibroblast activation protein (FAP) targeting chimeric antigen receptor macrophage and its construction method and application. The expression of FAP increases in senescent cells of various senescent diseases. Immune cells, especially macrophages, specifically eliminates senescent cells after expressing chimeric antigen receptor recognizing FAP protein, thereby reducing the pathogenic effect of senescent cells. Macrophages expressing the FAP chimeric antigen receptor can undergo M2-type polarization, which do not produce inflammatory factors to deteriorate age related diseases, have good infiltration ability to tissues with dense matrix, do not induce graft-versus-host disease and have high recognition efficiency of senescent cells and good phagocytic effect. This provides a new idea for preparing reagents for eliminating senescent cells, which have wide potential in practical application.

The invention belongs to the field of biological medicines, and relates to a drug-loaded nano-vesicle as well as a preparation method and application thereof. The drug-loaded nano-vesicle comprises a vesicle core and a drug-loaded nano-vesicle, wherein the vesicle core comprises siRNA (small interfering Ribonucleic Acid) capable of specifically targeting and silencing an NR1D1 gene; the vesicle membrane is formed by fusing an erythrocyte membrane, a macrophage membrane, cardiolipin, cholesterol and lecithin. The drug-loaded nano-vesicle can specifically target macrophages in a sepsis immunosuppression stage, has an intracellular response release function, recovers BMAL1 and IGF2BP2-ATP6V1B2 / ATP6V0c axis functions by inhibiting NR1D1 expression, reconstructs a macrophage phagocytosis function and lysosome-dependent bacterium removal capability, and can be used for preparing a drug-loaded nano-vesicle with a specific targeting function. The survival rate of sepsis immunosuppression model animals is obviously improved; and the bacterial load is reduced. Compared with a traditional electroporation method, the preparation method disclosed by the invention has the advantage that the encapsulation efficiency of siRNA is remarkably improved.

The invention relates to a method for separating and purifying polygonatum sibiricum oligosaccharide. According to the method, the polygonatum sibiricum polysaccharide and the filler or / and the filter aid are fully mixed and then separated and purified; wherein the filler is prepared from Sephadex G-15 (crosslinked glucose gel), DEAE-Sepharose CL-4B (agar gel) and Bio-Gel P-2 (polyacrylamide gel), the filter aid is prepared from kieselguhr, perlite, cellulose, activated carbon and red soil, and the method has the advantages that the Mwlt can be obviously improved; the yield of the 2KDa polygonatum sibiricum oligosaccharide is increased, and the effect of combined use of the filler and the filter aid is optimal. The addition of the filter aid can avoid the blockage of filler pores in the middle and later stages of elution, improve the elution performance of the filler on polysaccharide, and accelerate the elution and purification speed of the polygonatum kingianum oligosaccharide. Experiments show that the oligosaccharide can significantly enhance the proliferative activity and phagocytosis of macrophages, promote RAW264.7 cells to secrete TNF-alpha, IL-6, NO and other cell factors, and improve the cellular immunocompetence. The method has the characteristics of convenience, high efficiency and low cost, and has relatively high application value.

The invention relates to the technical field of microorganisms, in particular to compound probiotics capable of degrading indole and preventing or relieving nephropathy and application of the compound probiotics. The compound probiotics comprise bifidobacterium animalis subsp. Lactis YYS-J9 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) NO.28185 and bifidobacterium longum subsp. Longum YYS-BSM8 with the preservation number of CGMCC NO.28611. The invention further discloses a preparation method of the compound probiotics. Compared with the use of a single YYS-J9 strain or YYS-BSM8 strain, the two strains have synergistic effects after being compounded, the viable count is remarkably increased after mixed culture, the inhibition effect on pathogenic enterobacteria and the adhesion to intestinal cells are remarkably enhanced, the degradation capacity on indole and oxalic acid is higher, the proliferation and phagocytic activity of macrophages is remarkably improved, and the application range of the YYS-J9 strain and the YYS-BSM8 strain is widened. And when being applied to food, health-care products or medicines, the exopolysaccharide can be used for effectively preventing or improving nephropathy and kidney stone, regulating intestinal health and improving intestinal immunity.

The invention relates to a varied massinia, and in particular relates to a separated varied massinia P2-4 with broad-spectrum phagocytosis activity on pathogenic bacteria, and the varied massinia P2-4 is used for phagocytosis in a bacterium cracking manner, so that the activity of the varied massinia P2-4 is improved. The compound has phagocytosis activity on pathogenic bacteria such as pseudomonas aeruginosa, shewanella alginosa, aeromonas cainea, aeromonas hydrophila and photobacterium damsela; the Marsinia variabilis P2-4 provided by the invention can be applied to inhibition of pathogenic bacteria in an aquaculture water body; by adding the varied maleinia sp. P2-4 or the microbial inoculum thereof into the aquaculture feed, the immunity and / or the oxidation resistance and / or the disease infection resistance of the organism of aquaculture animals can be enhanced; the varied marssonia sp. P2-4 disclosed by the invention can be used as a feed additive for aquaculture or a biocontrol product for aquaculture, and can also be used for preventing and / or treating diseases of aquaculture animals.

The invention discloses an antibacterial peptide P1 and medical application thereof in treating sepsis. The amino acid sequence of the antibacterial peptide P1 is as shown in SEQ ID NO. 1. The antibacterial peptide P1 provided by the invention has a good treatment effect on a sepsis mouse CLP model. The antibacterial peptide P1 can play a good bactericidal effect by directly destroying cell walls and cell membranes of staphylococcus aureus; the antibacterial peptide P1 also has bacterial capture ability and immunomodulatory activity, and can relieve survival rate reduction induced by sepsis, liver and lung injury caused by sepsis, liver and lung injury caused by sepsis, and organ bacterial infection caused by sepsis. Cell walls and cell membranes of staphylococcus aureus are directly destroyed, and a network structure is formed in a hydrophobic environment to capture bacteria and promote phagocytosis of immune cells. The compound is a good novel antibiotic substitute product, and can be used for preparing drugs for treating sepsis.

The invention discloses a macrophage-polymer lipid nanoparticle composite drug delivery system, a preparation method thereof and application of the macrophage-polymer lipid nanoparticle composite drug delivery system in cryptococcus infection resistance. According to the drug delivery system, alpha-linolenic acid (ALA), high molecular weight chitosan oligosaccharide (HCOS) and amphotericin B (AmB) are used as raw materials to construct nanoparticles AmB-PLHNs, the nanoparticles are loaded in macrophages through the phagocytosis of the macrophages, and the AmB-PLHNs (at) M1 is constructed. AmB is a common medicine for clinically treating Cn infection, but has the problems of toxic and side effects on kidney and incapability of being transferred into the center. The AmB-PLHNs (at) M1 carries AmB-PLHNs to be transferred into the brain according to the blood-brain barrier penetrating characteristic of M1 type macrophages, and the brain entering efficiency of the medicine is improved. By combining the phagocytosis of macrophages on cryptococcus, the inflammation immune regulation function of the macrophages and the bacteriostatic action of the drug-loaded nanoparticles, the drug-loaded nano-particles are used for treating Cn central infection, and the toxic and side effects of AmB are reduced.

The invention discloses a monoluciferase-based ADCP biological activity detection method, which comprises the following steps: separating a mononuclear cell from a human peripheral blood mononuclear cell as an effector cell, phagocytizing a Raji cell transfected by Luciferase as a target cell by the mononuclear cell, acidifying and degrading the Raji cell in a phagocytic body, and degrading the Luciferase so as to attenuate a light-emitting signal, so that the ADCP biological activity is detected. The ADCP biological activity of the antibody therapeutic drug is accurately quantified by detecting the weakening of the light-emitting signal. According to the present invention, the method only needs to separate the mononuclear cells and perform Luciferase infection on the target cells, and only needs to add the luciferase substrate after the phagocytosis process, such that the luminescence value can be read by using the microplate reader, the operation process is simple, the steps are less, the time consumption is short, the high-throughput screening is achieved, and the new direction is provided for the ADCP detection.

The invention relates to application of anti-PTPRZ1 chimeric antigen receptor macrophages in lung cancer treatment, and belongs to the technical field of tumor targeted therapy. The invention constructs a novel chimeric antigen receptor (CAR) which comprises a coding sequence of a single-chain variable region fragment for specifically recognizing PTPRZ1, and a coding sequence of a CD8TM transmembrane region and a coding sequence of a CD3zeta intracellular signal transduction structural domain. The design ingeniously endows the chimeric antigen receptor (CAR) with high specificity, so that the chimeric antigen receptor (CAR) can accurately recognize and firmly bind to the surface of a tumor cell expressing PTPRZ1 protein. According to the present invention, the chimeric antigen receptor targeting PTPRZ1 is successfully transfected into the human macrophage to form the CAR-M. A flow cytometry verifies that compared with non-transfected macrophages (Mphi) or transfected macrophages lacking a specific target binding domain (CAR-M-delta), the CAR-M has the advantage that the efficiency of swallowing PTPRZ1 positive tumor cells is remarkably improved in the aspect of the efficiency of swallowing PTPRZ1 positive tumor cells. Therefore, the CAR-M constructed by the invention can be used as a potential treatment means for targeting PTPRZ1 expression tumors.

The invention relates to an alkali-resistant massinia sp., in particular to a separated alkali-resistant massinia sp. P2-6 with broad-spectrum phagocytosis activity on pathogenic bacteria, and the alkali-resistant massinia sp. P2-6 is used for phagocytosis in a bacterium splitting manner, and can be used for preparing the alkali-resistant massinia sp. P2-6 with broad-spectrum phagocytosis activity on pathogenic bacteria. The compound has phagocytosis activity on pathogenic bacteria such as aeromonas veronii, aeromonas hydrophila, aeromonas cainea, pseudomonas aeruginosa, shewanella alginate or photobacterium damsela and the like; the alkali-resistant Marsinia sp. P2-6 disclosed by the invention can be applied to inhibition of pathogenic bacteria in an aquaculture water body; alkali-resisting marssonia sp. P2-6 or a microbial agent thereof is added into an aquaculture feed, so that the organism immunity and / or oxidation resistance and / or disease infection resistance of aquaculture animals can be enhanced; the alkali-resistant Marsinia sp. P2-6 provided by the invention can be used as a feed additive for aquaculture or a biocontrol product for aquaculture, and can also be used for preventing and / or treating diseases of aquaculture animals.

The invention relates to the technical field of biological medicine, and provides a ginseng cell engineering tumor vaccine as well as a preparation method and application thereof. The ginseng cell engineering tumor vaccine comprises an exosome derived from a recombinant ginseng cell capable of expressing a tumor antigen; the recombinant ginseng cell capable of expressing the tumor antigen is obtained by introducing a recombinant plasmid containing tumor antigen DNA into a ginseng cell. According to the invention, ginseng cells in Chinese herbal medicines are taken as host cells for recombinant expression of tumor antigens, large-scale production of tumor vaccines can be realized through construction of an engineering recombinant cell system, biocompatibility and uniformity of the vaccines can be maintained, and safety risks can be reduced. Meanwhile, the prepared tumor antigen recombinant expression ginseng cell exosome can integrate the antigen, an adjuvant and a carrier, and the antigen phagocytosis, maturation and antigen peptide presentation capabilities of APCs are enhanced.

The invention belongs to the technical field of biological medicines, and particularly relates to an intracellular signal transduction region combination of a HER2-targeting chimeric antigen receptor and application of the intracellular signal transduction region combination. The chimeric antigen receptor containing the intracellular signal transduction region combination can keep the CAR positive rate, and can ensure the motility rate and the recovery amount of cells, so that the activity of CAR-immune cells is better ensured; immune cells of the chimeric antigen receptor containing the intracellular signal transduction region combination show significantly enhanced phagocytosis, killing and anti-depletion capabilities and T cell activation / activation level, and achieve stronger anti-tumor activity and stronger tumor wettability.

The invention discloses application of probiotic yeast microcapsules in drugs for targeted regulation of inflammatory macrophage immunity, and belongs to the technical field of biological medicines. As a novel medicine, the yeast microcapsule has the characteristics of engineering, convenience, low cost, high patient compliance, high safety and excellent targeting property, can be used as an oral medicine for treating chronic inflammatory disease rheumatoid arthritis, acts on mitochondria through oxidative stress and oxidative phosphoric acid pathways, inhibits excessive activation of macrophages, and has the effect of treating chronic inflammatory disease rheumatoid arthritis. Release of inflammatory factors is reduced, and inflammatory reaction is relieved; the yeast micro-capsule can promote the phagocytosis and antigen presentation function of macrophages and enhance the immune defense capability of a body, so that the immune function of the macrophages is adjusted, and the yeast micro-capsule shows huge potential in preparation of drugs for targeted adjustment of inflammatory macrophage immunity, and has a broad application prospect in preparation of drugs for targeted adjustment of inflammatory macrophage immunity. And a theoretical basis is provided for developing non-invasive, convenient and safe treatment of chronic inflammatory diseases such as rheumatoid arthritis.

The invention relates to a racemic polylactic acid injection filler microsphere containing gamma-polyglutamic acid as well as a preparation method and application of the racemic polylactic acid injection filler microsphere. The preparation method comprises the following steps: (1) injecting a racemic polylactic acid solution into a polyvinyl alcohol aqueous solution, homogenizing, and reacting at 30-40 DEG C for 4.5-5.5 hours to obtain PDLLA microspheres; (2) preparing a suspension from gamma-polyglutamic acid, sodium carboxymethyl cellulose and mannitol; and (3) adding the PDLLA microspheres into the suspension, uniformly mixing, and freeze-drying to obtain the gamma-polyglutamic acid-containing racemic polylactic acid injection filler microspheres. The prepared injection filler microspheres are high in yield, small in particle size, uniform in distribution, good in spherical appearance, free of adhesion, low in solvent residue and high in purity, nodules can be reduced to a great extent due to the fact that the particle size is not too large, and adverse reactions such as inflammation caused by phagocytosis of macrophages due to the fact that the particle size is too small are avoided; the compound is more suitable for being injected into a human body as a filler.

The invention provides heat-resistant bacillus pumilus P2-7 and application thereof in disease prevention and control of prawn culture, and belongs to the technical field of bioengineering. The heat-resistant bacillus pumilus P2-7 provided by the invention is preserved in Guangdong Microbial Culture Collection Center on November 4, 2024, and the preservation number of the heat-resistant bacillus pumilus P2-7 is GDMCC NO. 65408. The strain is different from the traditional antibacterial bacillus in antagonism mode, cannot secrete metabolites with antibacterial activity, plays a role in a phagocytosis mode, can remarkably remove / inhibit pathogenic bacteria in water, can effectively prevent and control shewanella disease of prawns, and has a good application prospect. The composition also has a good effect of simultaneously preventing septicemia, acute hepatopancreas necrosis, white spot syndrome and infectious subcutaneous and hematopoietic necrosis in prawn culture production.

The invention belongs to the technical field of nanogel preparations, and particularly relates to application of nanogel to preparation of anti-tumor drugs or preparation of the anti-tumor drugs. Experiments find that nanogel with proper hardness can promote expression of M1 related proteins CD86 and iNOS, and up-regulate expression of CD86 mRNA and iNOS mRNA, so that M2 type tumor related macrophages are reversely polarized into M1 type tumor related macrophages. Further research finds that after the nanogel is used for carrying out reverse polarization treatment on M2 type tumor-related macrophages, tumor cell proliferation can be inhibited, tumor cell apoptosis can be induced, and tumor cell phagocytosis can be realized. In addition, the nanogel with proper hardness is directly delivered into the tumor in an intratumor injection manner, so that the growth of the tumor can be effectively inhibited.

The invention relates to the technical field of microorganisms, in particular to compound probiotics for relaxing bowel and improving intestinal immunity and application thereof. The compound probiotics comprise a plant lactobacillus BXM2 strain with the preservation number of CGMCC (China General Microbiological Culture Collection Center) NO.16436 and a bifidobacterium longum subsp. Longum YYS-BSM8 strain with the preservation number of CGMCC NO.28611, and the ratio of the viable count of the plant lactobacillus BXM2 to the viable count of the bifidobacterium longum subsp. Longum YYS-BSM8 is (1-10): (1-10). After the two bacteria are compounded and combined, the gastrointestinal motility efficiency of zebra fish is accelerated, constipation is relieved, enteropathogenic bacteria are inhibited, the adhesive force of intestinal cells is improved, exopolysaccharides are produced at high yield, proliferation and phagocytic activity of macrophages are promoted, oxidative damage is remarkably relieved, and synergistic interaction is achieved in the aspects of improving the intestinal motility efficiency, relieving constipation and improving body immunity; the important application value is realized.

The invention relates to the technical field of biological medicine, and provides a Chinese herbal medicine vesicle-LNP hybrid tumor mRNA vaccine and application thereof. The tumor mRNA vaccine disclosed by the invention is obtained by hybridizing Chinese herbal medicine nano-vesicles and lipid nano-particles loaded with tumor antigen mRNA. According to the invention, the characteristic of good biocompatibility of Chinese herbal medicines is utilized, so that the safety risk of the cationic lipid carrier is reduced. By combining the characteristics of Chinese herbal medicines, the nano-vesicles are extracted, so that the LNP is promoted to more effectively target antigen-presenting cells, the uptake level of the antigen-presenting cells is promoted, the phagocytosis of mRNA is enhanced, and the targeting and transcriptional expression level of mRNA can be enhanced. Finally, the Chinese herbal medicine nano vesicle-LNP hybrid tumor mRNA vaccine can strengthen the curative effects of inhibiting tumor progression, tumor recurrence and tumor metastasis after the tumor mRNA vaccine is inoculated, and a path is opened up for the combination of the tumor mRNA vaccine and richer immunotherapy means.

The invention discloses a phagocytosis-resistant indigo engineering strain, which can sensitively respond to enteritis-related thiosulfate inflammatory factors, timely release a drug indigo to treat gastrointestinal inflammation, and release sfGFP signal molecules to assist in diagnosis and monitoring of diseases, and is very helpful for slowing down disease progression. In addition, through knockout of fhuA and trxA genes related to bacteriophage infection and knockin of an sspB-sspC-sspD-sspE gene cluster, the survival rate of the strain in the intestinal tract can be improved, and the treatment and diagnosis effects of the strain are improved.

The invention discloses application of ANXA2 protein in improving immunoreaction of sheep to mycoplasma pneumoniae, and finds that the ANXA2 protein is sheep mycoplasma pneumoniae receptor protein and can be combined with the sheep mycoplasma pneumoniae, meanwhile, the protein is also TLR2 receptor inhibition protein, and after expression of an ANXA2 gene is interfered and pulmonary alveolar epithelial cells are infected by the sheep mycoplasma pneumoniae, the protein can be combined with the sheep mycoplasma pneumoniae and can be combined with the TLR2 receptor inhibition protein. The autophagy response of the cells is enhanced, and the cell proliferation function is recovered; and after the ANXA2 gene is interfered, the phagocytosis and clearance of the mycoplasma by the macrophages are also enhanced. It is shown that the immune response of cells to mycoplasma can be improved by knocking out the ANXA2 gene, damage of mycoplasma pneumoniae to the cells or sheep is reduced, and the time required for variety improvement can be remarkably shortened when the ANXA2 gene is used for later disease-resistant variety breeding.

The invention belongs to the technical field of biological medicine, and particularly relates to a screening method of a recombinant protein for inhibiting the phagocytic function of macrophages on myelin sheath protein and a hydrogel preparation. The invention firstly provides a screening method of the recombinant protein, which comprises the following steps: co-culturing a recombinant protein solution and macrophages in an environment rich in myelin protein, and detecting various indexes to screen out the recombinant protein capable of remarkably inhibiting the phagocytic function of the macrophages on the myelin protein. The invention discloses regulation and control of the macrophage phenotypic change and the relationship between the macrophage phenotypic change and the MD phagocytosis function of the specific recombinant protein for the first time, and provides a new thought for screening the recombinant keratin with a specific function.

Provided are a postbiotic of Weizmannia coagulans, and a preparation method therefor, and a use thereof. The postbiotic comprises inactivated bacteria and / or lipoteichoic acid. The postbiotic can enhance the phagocytosis activity of macrophages, the cytokine and NO secretion ability of macrophages, and the expression levels of immune-function-related genes and proteins, and has an effect of inducing human PBMC cells to kill cancer cells.

The application discloses a use of Ejiao Qianggu oral liquid in regulating immunity, and particularly relates to an improving effect of the Ejiao Qianggu oral liquid on an immune system, which is realized by the following aspects. On one hand, the Ejiao Qianggu oral liquid promotes proliferation and transformation (mainly early T lymphocytes and part of B lymphocytes) and active functions of spleen lymphocytes; on the other hand, the Ejiao Qianggu oral liquid improves phagocytosis of macrophages. The Ejiao Qianggu oral liquid has the following characteristics: firstly, the Ejiao Qianggu oral liquid acts on early lymphocyte maturation, and has no significant effect on proliferation of peripheral blood lymphocytes; secondly, the Ejiao Qianggu oral liquid can significantly act on immune target organs, thymus and spleen tissues, and does not excessively stimulate the spleen, unlike positive drugs such as colony stimulating factor which can cause significant edema of the spleen; and thirdly, the Ejiao Qianggu oral liquid has a significant recovery effect on body weight, white blood cells, lymphocytes, red blood cells and hemoglobin in blood of patients with low immunity.

The application provides a momordica root polysaccharide and a preparation method and application thereof, and belongs to the technical field of natural product development. The preparation method of the momordica root polysaccharide comprises the following steps: drying and crushing momordica roots, and removing fat by ethanol reflux; after water extraction and alcohol precipitation, and removing protein, a momordica root crude polysaccharide is obtained; and the momordica root crude polysaccharide is sequentially separated and purified by DEAE-52 cellulose column and Sephadex LH20 gel column to obtain the momordica root refined polysaccharide. The preparation method has the advantages that the polysaccharide obtained by directly extracting water in the prior art has a narrow molecular weight distribution range and better immune enhancement activity. Experimental results show that the momordica root polysaccharide can stimulate RAW264.7 cells to secrete NO, TNF-alpha and IL-6 factors, enhance the phagocytosis of RAW264.7 cells, and thus enhance the cell immune function, and can be applied to the development of products for improving immunity.